Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion April 7, 2026 4:30 PM EDT
Company Participants
Jacquie Ross – Senior Vice President of Treasury and Investor Relations
Daniel O’Day – Chairman & CEO
Dietmar Berger – Chief Medical Officer
Cindy Perettie – Executive Vice President of Kite
Andrew Dickinson – Chief Financial Officer
Conference Call Participants
Tyler Van Buren – TD Cowen, Research Division
Geoffrey Meacham – Citigroup Inc., Research Division
Michael Yee – UBS Investment Bank, Research Division
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Carter Gould – Cantor Fitzgerald & Co., Research Division
Brian Abrahams – RBC Capital Markets, Research Division
Daina Graybosch – Leerink Partners LLC, Research Division
James Shin – Deutsche Bank AG, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Amy Li – Jefferies LLC, Research Division
Louise Chen – Scotiabank Global Banking and Markets, Research Division
Anish Nikhanj – Truist Securities, Inc., Research Division
Luke Herrmann – Robert W. Baird & Co. Incorporated, Research Division
Presentation
Operator
Good afternoon. Thank you for attending today’s Gilead Sciences update on proposed Tubulis, Ouro and Arcellx acquisitions call. My name is Tamia, and I will be your moderator for today’s call. [Operator Instructions]
I would now like to pass the conference over to your host, Jacquie Ross, SVP, Treasurer and Head of Investor Relations.
Jacquie Ross
Senior Vice President of Treasury and Investor Relations
Thank you, Tamia. Good afternoon, everyone, and welcome to today’s call to discuss this morning’s announcement of Gilead’s definitive agreement to acquire Tubulis in addition to other recently announced transactions with Arcellx and Ouro. A press release, in addition to the presentation slides from today’s call are available on the Investors section of our website at gilead.com.
The speakers on today’s call will be our Chairman and Chief Executive Officer, Daniel O’Day; our Chief Medical Officer, Dietmar Berger; the
